Dr. Prowse is an accomplished leader in the healthcare industry with more than 20 years of experience at small, mid and large cap biotechnology companies and investment banks.
Most recently, Dr. Prowse served as senior vice president of strategy and corporate development for Rocket Pharmaceuticals, Inc., where she provided leadership and execution across financing transactions and other strategic initiatives contributing to the company's successful growth from small to mid-cap stage.
Prior to this role, she was vice president of strategy, corporate development and investor relations officer at Inotek Pharmaceuticals Corp., where she was instrumental in driving the strategy and leading the merger transaction with Rocket Pharmaceuticals, Inc. Dr. Prowse served in similar strategy and investor relations roles at Biogen, Inc., Human Genome Sciences and Ionis Pharmaceuticals, Inc., as well as vice president at Leerink Swann.
She holds a Ph.D. in Biomedical Sciences from the University of California, San Diego School of Medicine and a B.S. in Biomedical Engineering from the UCSD School of Engineering.
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody platform technology.
GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a range of nucleic acid payloads to select cells.
This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes.
Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer